Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.51 |
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543536 | 0.81 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL1543410 | 0.81 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL1543522 | 0.77 | PIK3CA (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL1544125 | 0.77 | PIK3CA (0.59) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL730423 | 0.76 | PIK3CA (0.72) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL1543975 | 0.76 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL1543567 | 0.76 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL1543972 | 0.76 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL1543570 | 0.76 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL3124947 | 0.76 | MAPK1 (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | claimed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | claimed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | PIK3CA 1/4885PIK3CD 5/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.